Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10963816 | Vaccine | 2015 | 8 Pages |
Abstract
Hib vaccine was highly cost-effective from both societal and governmental perspectives. However, with GAVI support ending in 2016, the government will face a six-fold increase in its vaccine budget at the 2013 vaccine price. The variability of vaccine market prices adds an element of uncertainty. Increased government commitment and improved resource allocation decision making will be necessary to retain Hib vaccine.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Phuc Le, Ulla K. Griffiths, Dang Duc Anh, Luisa Franzini, Wenyaw Chan, J. Michael Swint,